View CME-certified presentations and downloadable slides covering the most up-to-date clinical trial data on neuroendocrine tumors (NETs) from the NANETS 11th Annual Multidisciplinary NET Disease Symposium.
0.75 AMA PRA Category 1 Credit™
Oct 10, 2018
Oct 10, 2019
Featured Expert: Wasif M. Saif, MD
Featured Expert: Jonathan Strosberg, MD
Featured Expert: N. Arvind Dasari, MD
N. Arvind Dasari, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Scott Paulson, MDTexas Oncology
Dallas, Texas, United States
Wasif M. Saif, MDTufts Medical Center
Boston, Massachusetts, United States
Jonathan Strosberg, MDMoffitt Cancer Center
Tampa, Florida, United States
This educational activity is designed for medical oncologists, endocrinologists, gastroenterologists and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors.
After successful completion of this educational activity, participants should be able to:
- Describe recent findings on the contemporary use of somatostatin analogue therapy in the management of gastroenteropancreatic NETs (GEP-NETs)
- Assess clinical trial data describing treatment options for patients with neuroendocrine tumors
This educational activity is supported by a grant from Ipsen.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the post-test are available on the video player pages.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Saif has disclosed that he has received honoraria for promotional speakers’ bureau(s) from Ipsen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.